1/7
08:30 am
fblg
FibroBiologics CEO Issues Letter to Shareholders
High
Report
FibroBiologics CEO Issues Letter to Shareholders
1/6
09:55 am
fblg
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Medium
Report
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
1/6
08:30 am
fblg
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
High
Report
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
1/5
09:15 am
fblg
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease [Yahoo! Finance]
Low
Report
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease [Yahoo! Finance]
1/5
08:30 am
fblg
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
Low
Report
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
12/31
08:30 am
fblg
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
Medium
Report
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
12/16
04:05 pm
fblg
FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Medium
Report
FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
12/15
08:00 am
fblg
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
High
Report
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
12/10
09:19 am
fblg
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions [Yahoo! Finance]
Medium
Report
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions [Yahoo! Finance]
12/10
08:30 am
fblg
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
Medium
Report
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
11/26
08:30 am
fblg
FibroBiologics Announces Payoff of Outstanding Debt
Low
Report
FibroBiologics Announces Payoff of Outstanding Debt
11/25
04:56 pm
fblg
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]
Low
Report
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]
11/25
04:05 pm
fblg
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Low
Report
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11/24
09:00 am
fblg
FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
High
Report
FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11/20
08:22 am
fblg
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Medium
Report
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
11/20
08:00 am
fblg
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
Medium
Report
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
11/19
07:03 pm
fblg
FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Low
Report
FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11/19
08:36 am
fblg
FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
High
Report
FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11/5
07:19 am
fblg
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/3
08:03 am
fblg
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Low
Report
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
10/31
04:53 pm
fblg
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
10/31
04:30 pm
fblg
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/24
08:30 am
fblg
FibroBiologics to Present at Bio-Europe 2025
Medium
Report
FibroBiologics to Present at Bio-Europe 2025